Johnson & Johnson Unveils Details On Ottava Soft-Tissue Robot, Chasing Intuitive, Medtronic
Executive Summary
J&J said its Ottava robotic platform has six robotic arms, “zero footprint,” and can be used for various procedures.
You may also be interested in...
After Two-Year Delay, J&J Plans To Start Trial Ottava Surgical Robot In 2024
J&J originally projected its Ottava soft-tissue robotic surgery system would enter first-in-human trials in 2022 and reach the market by 2023, but the development has been delayed by technical challenges and COVID-19-related disruptions. Now the company plans to start trials of a four-armed version of the device in about a year.
Fly Me To The Moon: French Company 'Empowers' Surgeons With Maestro
The Paris-based company has developed Maestro, a lightweight robotic assistant for use in laparoscopic procedures.
News We’re Watching – FDA Nixes Neuralink Trials, Layoffs at J&J, Novel Knee Implants
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.